New targets and therapies for gastrointestinal stromal tumors

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GIST) are primarily driven by aberrant receptor tyrosine kinase (RTK) signaling, often due to mutations in KIT or PDGFRA.
• Tyrosine kinase inhibitors (TKIs) have transformed GIST treatment, but resistance inevitably develops in most patients.
• Understanding the molecular basis of TKI resistance is crucial for developing new therapeutic strategies.

Purpose of the Study:

• To review novel and promising therapeutic approaches for overcoming heterogeneous TKI resistance in GIST.
• To explore emerging strategies targeting specific mutations, multiple RTKs, downstream pathways, KIT expression, cell cycle, and immunotherapy.

Main Methods:

• Review of current literature on GIST resistance mechanisms and emerging therapies.
• Analysis of novel therapeutic agents including new TKIs, multi-RTK inhibitors, pathway inhibitors, and immunotherapeutics.
• Discussion of personalized medicine approaches and monitoring strategies like liquid biopsy.

Main Results:

• Several novel therapeutic avenues are being explored to combat TKI resistance in GIST.
• These include next-generation TKIs, multi-targeted agents, and drugs affecting KIT expression and downstream signaling.
• Immunotherapies and cell cycle inhibitors also represent promising strategies.

Conclusions:

• Combinational approaches may be beneficial for treating refractory GIST due to heterogeneous resistance.
• Personalized treatment strategies, guided by molecular profiling of resistant disease, are essential.
• Liquid biopsy offers a promising tool for monitoring treatment response in GIST patients.